

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for September 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Angita Pharma Inc.	AG-Fluoxetine	Prozac	FLUOXETINE HCL	10mg	capsule	02485052
Jamp Pharma Corporation	Jamp Methimazole	Tapazole	METHIMAZOLE	10 mg	tablet	02490633
Jamp Pharma Corporation	Jamp Rasagiline	Azilect	RASAGILINE MESYLATE	0.5 mg	tablet	02491974
Jamp Pharma Corporation	Jamp Rasagiline	Azilect	RASAGILINE MESYLATE	1 mg	tablet	02491982